Black Diamond brings in ex-GSK CEO Bob Ingram to chart new path in precision oncology
Black Diamond Therapeutics started the year with a more than $200 million vault onto Nasdaq and a clinic-bound allosteric therapy — and now, the young biotech has GlaxoSmithKline vet Bob Ingram to help pave its way.
Ingram is set to take the reins from Black Diamond’s founding chairman Brad Bolzon, the company announced on Tuesday. The Massachusetts-based biotech was the first to launch out of Versant’s Ridgeline discovery engine in 2018, co-founded by David Epstein and Elizabeth Buck, former developers of the cancer drug Tarceva. Bolzon will remain on the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.